✦ LIBER ✦

A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia

✍ Scribed by Eva Hellström-Lindberg; Karl-Henrik Robèrt; Gösta Gahrton; Greger Lindberg; Ann-Mari Forsblom; Yvonne Kock; Åke Öst

Book ID: 114712727
Publisher: John Wiley and Sons
Year: 1992
Tongue: English
Weight: 791 KB
Volume: 81
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.1992.tb02982.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of a multicenter phase II trial

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib

✍ Florian Heidel; Jorge Cortes; Frank G. Rücker; Walter Aulitzky; Laurie Letvak; T 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

188Re or 90Y-labelled anti-CD66 antibody

188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I–II study

✍ Mark Ringhoffer; Norbert Blumstein; Bernd Neumaier; Gerhard Glatting; Stephanie 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

A predictive model for the development o

A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C

✍ Peter A.L Bonis; Myron J Tong; Lawrence M Blatt; Andrew Conrad; John L Griffith 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 117 KB

A non-randomised dose-escalating phase I

A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies

✍ Didier Bouscary; Laurence Legros; Micheline Tulliez; Stéphanie Dubois; Béatrice 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 383 KB

PCV121 Using International HTA Guideline

PCV121 Using International HTA Guidelines to Inform UK Health Care Decision-Making: A Case Study of Ticagrelor in Combination with Low-Dose Aspirin for the Treatment of Acute Coronary Syndromes

✍ P. Dequen; A.J. Sutton; C. McGrath; K. Abrams 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Low-dose cytosine arabinoside (LD-AraC)

Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group

✍ Zwierzina, H; Suciu, S; Loeffler-Ragg, J; Neuwirtova, R; Fenaux, P; Beksac, M; H 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 116 KB